KHK7580
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism
Conditions
Secondary Hyperparathyroidism
Trial Timeline
Sep 28, 2015 → Dec 28, 2016
NCT ID
NCT02549404About KHK7580
KHK7580 is a phase 3 stage product being developed by Kyowa Kirin for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT02549404. Target conditions include Secondary Hyperparathyroidism.
What happened to similar drugs?
6 of 20 similar drugs in Secondary Hyperparathyroidism were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03280264 | Phase 3 | Completed |
| NCT02549417 | Phase 3 | Completed |
| NCT02549404 | Phase 3 | Completed |
| NCT02143271 | Phase 1 | Completed |
| NCT01935856 | Phase 1/2 | Completed |
Competing Products
20 competing products in Secondary Hyperparathyroidism